Cost-Effectiveness Analyses Fail to Consider Health Equity

Although an important tool in assessing a drug’s value, cost-effectiveness analyses (CEAs) fail to account for health equity. Important information missing from CEAs includes socioeconomic status and ethnicity—critical factors when it comes to assessing outcomes. A group of healthcare stakeholders called for key changes in health economics and outcomes research (HEOR), including methods that consider health equity and clinical trials that reflect the diverse populations the novel therapeutic is intended to treat.

“This progress in pioneering new methods and improved data signals an important step in the right direction. However, support and collaboration from all types of healthcare stakeholders will be needed to develop and use these equity-informative methods in decision making across geographies, and to establish new best practices.” Read more here.

(Source: tHEORetically Speaking – HealthEconomics.Com, 11/21)